What Investors Got Wrong About QuidelOrtho Before A 53% Slide

Simply Wall St.00:40

QuidelOrtho looked like a classic mismatch between headlines and holdings. Results on record showed revenue and net income improving year on year, yet the share price told a very different story. For ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2677960744?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice1-card/1788954194987","is_english":true,"pubTime":"2026-10-23 00:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677960744","market":"sg","top_or_hot":-1,"title":"What Investors Got Wrong About QuidelOrtho Before A 53% Slide","media":"Simply Wall St.","content":"<div>\n<p>QuidelOrtho looked like a classic mismatch between headlines and holdings. Results on record showed revenue and net income improving year on year, yet the share price told a very different story. For ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/what-investors-got-wrong-about-quidelortho-before-a-53-slide\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Investors Got Wrong About QuidelOrtho Before A 53% Slide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Investors Got Wrong About QuidelOrtho Before A 53% Slide\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-23 00:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/what-investors-got-wrong-about-quidelortho-before-a-53-slide><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QuidelOrtho looked like a classic mismatch between headlines and holdings. Results on record showed revenue and net income improving year on year, yet the share price told a very different story. For ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/what-investors-got-wrong-about-quidelortho-before-a-53-slide\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/what-investors-got-wrong-about-quidelortho-before-a-53-slide","article_id":"2677960744","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice1-card/1788954194987"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/what-investors-got-wrong-about-quidelortho-before-a-53-slide","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2677960744","pubTimestamp":1792687226,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"QuidelOrtho looked like a classic mismatch between headlines and holdings. Results on record showed revenue and net income improving year on year, yet the share price told a very different story. For QuidelOrtho shareholders, the loss over the past year was 52.8%, including dividends. If you had been weighing a position back in October 2025, which early signals would have mattered most before that outcome unfolded?\nQuidelOrtho is not the only name tied to this theme. Zero in on 37 healthcare...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","BK4211":"区域性银行","BK4198":"医疗保健用品","QDEL":"窥得儿医药","BK4082":"医疗保健设备"},"translate_title":"在下滑 53% 之前，投资者对 QuidelOrtho 的看法是什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QDEL":0.9,"ISBC":1.5},"content_text":"QuidelOrtho looked like a classic mismatch between headlines and holdings. Results on record showed revenue and net income improving year on year, yet the share price told a very different story. For QuidelOrtho shareholders, the loss over the past year was 52.8%, including dividends. If you had been weighing a position back in October 2025, which early signals would have mattered most before that outcome unfolded? QuidelOrtho is not the only name tied to this theme. Zero in on 37 healthcare AI stocks and compare how each one is priced. AdvertisementThe Two Stories QuidelOrtho Investors Were Weighing QuidelOrtho shares cost US$29.83 at the start of the period, and investors had to decide which future felt more realistic. The optimistic narrative pointed to a Fair Value of US$40.33, a rough guide to what the price could be if its assumptions played out. It was built on 2.6% annual revenue growth and profit margins rising from a loss to 0.6%. That view leaned on global expansion and decentralized testing as long-term supports. The cautious narrative anchored on a Fair Value of US$26, using 2.5% annual revenue growth and profit margins reaching 12.5% as key assumptions. It also warned that high debt and restructuring costs might squeeze flexibility if conditions turned. NasdaqGS:QDEL 1-Year Stock Price Chart What The QuidelOrtho Results Actually Tested QuidelOrtho later reported Q2 2026 revenue of US$630.9 million and a smaller net loss of US$92.9 million. Net margin improved from a loss of 41.6% in Q2 2025 to a loss of 14.7%, which pointed toward better efficiency but still fell short of the optimistic case that relied on a move into positive profitability. The lesson travels well. When a story leans on future margin repair, track the reported net margin and absolute profit each quarter to see whether the path to break-even is actually appearing. What QuidelOrtho’s Lower Price Now Asks You To Believe Today QuidelOrtho trades at US$14.08. The selected Narrative’s Fair Value sits above that level and leans on a repair story built around cash generation, a cleaner balance sheet, and steadier contribution from Labs and Immunohematology rather than blockbuster top line expansion. The key assumption a buyer must weigh is whether core lab and Immunohematology contracts outside China can hold mid single digit growth while cost savings and portfolio tweaks steadily lift margins and cash flow. \"QuidelOrtho’s Labs and Immunohematology franchises outside China, which management indicates represent the majority of revenue and are tied to long contracts and recurring consumables, could support a richer earnings profile if investors begin to ascribe a higher multiple to this more visible mid single digit growth stream, relative to the volatile respiratory and China exposed portions of the business.\" The price and this Narrative do not agree. → Uncover what this Narrative says QuidelOrtho is actually worth Which Company Could Surprise You Next? Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.  Company 1 - 21% below our estimate - supplies liquid cooling and power systems tailored to intensive AI server racks. Company 2 - 40% below our estimate - expands from solar trackers into storage and inverters to deepen long-term project revenue. Company 3 - 39% below our estimate - scales device trade-in and refurbishment programs as recycling incentives shift phones into resale channels.  That is three of the list. See all 33 potentially undervalued companies → This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if QuidelOrtho might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677960744","isCrawlerRequest":true}